Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2a, Multi-Center Open-Label Study to Evaluate the Safety and Efficacy of Combination Treatment With MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients With Recurrent/Metastatic HPV Associated Head and Neck Squamous Cancer

NCT03162224 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT03162224
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03162224 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2a, Multi-Center Open-Label Study to Evaluate the Safety and Efficacy of Combination Treatment With MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients With Recurrent/Metastatic HPV Associated Head and Neck Squamous Cancer
Lead sponsor
MedImmune LLC
Phase
Phase 1/2
Overall status
Completed
Start date
June 26, 2017
Completion date
March 19, 2021
Enrollment
35 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer, human papilloma virus